Literature DB >> 23830805

Eukaryotic translation initiation factors in cancer development and progression.

Rita Spilka1, Christina Ernst, Anita Kuldeep Mehta, Johannes Haybaeck.   

Abstract

Eukaryotic gene expression is a complicated process primarily regulated at the levels of gene transcription and mRNA translation. The latter involves four main steps: initiation, elongation, termination and recycling. Translation regulation is primarily achieved during initiation which is orchestrated by 12 currently known eukaryotic initiation factors (eIFs). Here, we review the current state of eIF research and present a concise summary of the various eIF subunits. As eIFs turned out to be critically implicated in different oncogenic processes the various eIF members and their contribution to onset and progression of cancer are featured.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Eukaryotic initiation factors; Translation initiation

Mesh:

Substances:

Year:  2013        PMID: 23830805     DOI: 10.1016/j.canlet.2013.06.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   9.756


  68 in total

1.  Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer.

Authors:  Zhifeng Lin; Liwen Xiong; Qiang Lin
Journal:  Med Oncol       Date:  2015-05-26       Impact factor: 3.064

Review 2.  Induction of endoplasmic reticulum stress as a strategy for melanoma therapy: is there a future?

Authors:  David S Hill; Penny E Lovat; Nikolas K Haass
Journal:  Melanoma Manag       Date:  2014-12-04

3.  Knockdown of eukaryotic translation initiation factor 3 subunit D (eIF3D) inhibits proliferation of acute myeloid leukemia cells.

Authors:  Guo-Zhen Liu; Ji-Zhu Liu; Xiao-Qing Li; Li Zhang; Shuang-Jing Li; Tai-Wu Xiao; Jing-Xia Wang; Guang-Yao Li; Yusen Liu
Journal:  Mol Cell Biochem       Date:  2017-08-12       Impact factor: 3.396

4.  A harmine-derived beta-carboline displays anti-cancer effects in vitro by targeting protein synthesis.

Authors:  Annelise Carvalho; Jennifer Chu; Céline Meinguet; Robert Kiss; Guy Vandenbussche; Bernard Masereel; Johan Wouters; Alexander Kornienko; Jerry Pelletier; Véronique Mathieu
Journal:  Eur J Pharmacol       Date:  2017-03-18       Impact factor: 4.432

5.  Kinetic pathway of 40S ribosomal subunit recruitment to hepatitis C virus internal ribosome entry site.

Authors:  Gabriele Fuchs; Alexey N Petrov; Caleb D Marceau; Lauren M Popov; Jin Chen; Seán E O'Leary; Richard Wang; Jan E Carette; Peter Sarnow; Joseph D Puglisi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-16       Impact factor: 11.205

6.  Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Authors:  Verena Paulitschke; Ossia Eichhoff; Christopher Gerner; Philipp Paulitschke; Andrea Bileck; Thomas Mohr; Phil F Cheng; Alexander Leitner; Emmanuella Guenova; Ieva Saulite; Sandra N Freiberger; Anja Irmisch; Bernhard Knapp; Nina Zila; Theodora-Pagona Chatziisaak; Jürgen Stephan; Joanna Mangana; Rainer Kunstfeld; Hubert Pehamberger; Ruedi Aebersold; Reinhard Dummer; Mitchell P Levesque
Journal:  EMBO J       Date:  2019-06-26       Impact factor: 11.598

7.  Knockdown of eIF3D inhibits breast cancer cell proliferation and invasion through suppressing the Wnt/β-catenin signaling pathway.

Authors:  Yan Fan; Yufei Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 8.  Regulation of global and specific mRNA translation by the mTOR signaling pathway.

Authors:  Neethi Nandagopal; Philippe P Roux
Journal:  Translation (Austin)       Date:  2015-02-02

Review 9.  The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.

Authors:  Nicholas Burwick; Bertal H Aktas
Journal:  Expert Opin Ther Targets       Date:  2017-10-30       Impact factor: 6.902

10.  High Paip1 Expression as a Potential Prognostic Marker in Hepatocellular Carcinoma.

Authors:  Hayeon Kim; Wonkyung Jung; Aeree Kim; Han Kyeom Kim; Baek-Hui Kim
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.